Navigation Links
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
Date:6/30/2011

ions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry of approximately 1,500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full Prescribing Information at www.provenge.com or call 1-877-336-3736.

About Prostate Cancer

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in men in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 240,890 new cases and approximately 33,720 men expected to die from the disease in 2011.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is t
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Biddeford, ME (PRWEB) December 18, 2014 ... founding director of the Center for Excellence in the ... of New England, has been selected as a member ... He is the first neuroscientist from Maine to receive ... a nonprofit organization supported entirely by the Dana Foundation. ...
(Date:12/19/2014)... With only 2 weeks left of ... Sartorius Biohit products . The product specials include Buy ... Pipette Trade-in Program, and free pipette tips. , Sartorius ... the world. They are ideal for lab technicians performing ... ,     Full volume range of 0.1 uL to ...
(Date:12/17/2014)... The Activated Carbon Manufacturing industry ... IBISWorld updated its original industry research report. , ... intensified focus on environmental policy. Over the five years ... power plants and a range of other industrial facilities ... Sarah Kahn, “a range of downstream industrial sectors rely ...
(Date:12/17/2014)... December 17, 2014 Once more, EMAAR ... a larger packaged waste water treatment plant to phase ... Economic City (KAEC). Two years ago Bioshaft successfully supplied ... Development, serving two residential towers with an occupancy of ... a quarter million gallons per day and was signed ...
Breaking Biology Technology:UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3
... Key words: ... Imaging Beads, , ... pro-inflammatory cytokines with potent leukocyte activation and/or chemotactic activity in ... C, and CXC3) based on the number and sequential relationship of ...
... J. Chartier and H.C. Birnboim , DNA Genotek Inc., ... DNA collected with Oragene works well with TaqMan SNP Genotyping Assays. , ... detected., , ... Single-nucleotide polymorphisms (SNPs) are highly abundant, and are estimated , ...
... , , ... Research Organics, Inc.is an ISO 9001:2000 primary manufacturer and leading ... for molecular biology, , diagnostics, cell culture, ... , Founded in 1953, Research Organics pioneered manufacture ...
Cached Biology Technology:The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 2The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 3The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System 4Oragene is compatible with TaqMan SNP genotyping 2Oragene is compatible with TaqMan SNP genotyping 3Research Organics 2Research Organics 3
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... Jude Children,s Research Hospital Washington University Pediatric Cancer ... half of a subtype of childhood brain tumor that ... evidence the tumors are susceptible to drugs already in ... brain tumors known as low-grade gliomas (LGGs). These slow-growing ...
... stents can keep clogged leg arteries open, preventing ... at the Society of Interventional Radiology,s 38th Annual ... disease (or PAD) is becoming increasingly prevalent due ... diabetes epidemics," said Robert A. Lookstein, M.D., FSIR, ...
... 14, 2013)Frozen balls of ice can safely kill cancerous tumors ... prospective multicenter trial of cryoablation. The results are being presented ... in New Orleans. "Cryoablation has potential as a treatment ... parts of the body and could prolong the lives of ...
Cached Biology News:Gene sequencing project finds new mutations to blame for a majority of brain tumor subtype 2Gene sequencing project finds new mutations to blame for a majority of brain tumor subtype 3Drug-coated stents prevent leg amputation 2Icy therapy spot treats cancer in the lung 2